Carmell Therapeutics executed a definitive agreement and plan of merger with Axolotl Biologix, a regenerative medicine company developing human amnion-based allograft products for active soft tissue repair, orthopedic and other indications.
Axolotl Biologix offers regenerative medicine treatment applications with clinical benefits found to stimulate cellular growth and repair of damaged cells and tissues. The company is presently enrolling a Phase I/II clinical trial for ankle osteoarthritis.
As of June 30, 2023, Axolotl achieved approximately $50 million in unaudited trailing 12-month (TTM) net revenue and approximately $5 million in unaudited TTM EBITDA from the sales of its products.
Per agreement terms, Axolotl’s shareholders will receive $65 million in cash and shares, plus up to $75 million linked with the achievement of certain revenue and business milestones. Upon closing, Axolotl will operate as wholly-owned subsidiary of Carmell.
Carmell Therapeutics is developing allogeneic plasma-based biomaterials that are designed to boost regenerative pathways across a variety of bone and soft tissue indications. Carmell received FDA clearance for a clinical trial to study accelerated healing and reduced infections in open tibia fractures with intramedullary rodding, and expects to initiate a Phase II trial for foot/ankle fusion. Preclinical development is also underway in spinal fusion, dental bone graft substitute and other applications.
Carmell Therapeutics executed a definitive agreement and plan of merger with Axolotl Biologix, a regenerative medicine company developing human amnion-based allograft products for active soft tissue repair, orthopedic and other indications.
Axolotl Biologix offers regenerative medicine treatment applications with clinical benefits found to...
Carmell Therapeutics executed a definitive agreement and plan of merger with Axolotl Biologix, a regenerative medicine company developing human amnion-based allograft products for active soft tissue repair, orthopedic and other indications.
Axolotl Biologix offers regenerative medicine treatment applications with clinical benefits found to stimulate cellular growth and repair of damaged cells and tissues. The company is presently enrolling a Phase I/II clinical trial for ankle osteoarthritis.
As of June 30, 2023, Axolotl achieved approximately $50 million in unaudited trailing 12-month (TTM) net revenue and approximately $5 million in unaudited TTM EBITDA from the sales of its products.
Per agreement terms, Axolotl’s shareholders will receive $65 million in cash and shares, plus up to $75 million linked with the achievement of certain revenue and business milestones. Upon closing, Axolotl will operate as wholly-owned subsidiary of Carmell.
Carmell Therapeutics is developing allogeneic plasma-based biomaterials that are designed to boost regenerative pathways across a variety of bone and soft tissue indications. Carmell received FDA clearance for a clinical trial to study accelerated healing and reduced infections in open tibia fractures with intramedullary rodding, and expects to initiate a Phase II trial for foot/ankle fusion. Preclinical development is also underway in spinal fusion, dental bone graft substitute and other applications.
Copy to clipboard 
